In this review, we describe the principles of ICM, summarize its use as a sensitive biomarker of CFTR function, and examine recent studies using ICM as an outcome measure of response to CFTR-directed therapeutics, and how the use of ICM may contribute to further improvement in personalized medicine eventually for all patients with CF. This evidence concerns the gene CFTR and cystic fibrosis.